Effectiveness of Potassium Supplement in Hypokalemic PD Patients: A Stratified Randomized Controlled Trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

TCTR

Registry ID

TCTR20190725004

Enrollment

192

Registered

2019-07-25

Start date

2020-01-08

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypokalemia in PD patient Peritonitis Hospitalization Cardiovascular mortality All-cause mortality Hypokalemia Peritoneal dialysis Peritonitis Potassium supplement

Interventions

Supplement potassium tablet to keep serum potassium level 4.0&#45

5.0 mEq/L following protocol:Protocol potassium supplement 1. Initial phase 1.1 If K 5.5 mEq/L Rx: STOP Enpott&#44

Kalimate 30 gm oral&#44

and follow up next 2 weeks. *** If Hyperkalemia with EKG abnormality related to hyperkalemia&#44

patients were admitted and treated aggressively to decrease serum potassium. And If this situation occurs more than 1 time&#44

the patients would be asked for excluding from study.,Supplement potassium intermittent or continuous to correct hypokalemia but the goal is keep serum potassium above 3.5 mEq/L and may either intermi

Active Comparator Drug,Active Comparator Other

Protocol potassium supplement,Conventional potassium supplement

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. End-stage kidney disease on peritoneal dialysis 2. Age 18-80 years. 3. Perform peritoneal dialysis more than 3 months. 4. Serum potassium less than 3.5 mEq/L from previous 6 months (Spotted serum potassium less than 3.5 mEq/L at least 3 visits or time-average serum potassium < 3.5 mEq/L)

Exclusion criteria

Exclusion criteria: 1. Recent peritonitis within 3 months 2. Hybrid with hemodialysis 3. Gastrointestinal tract disease that cannot absorbed potassium supplement. 4. Liver cirrhosis CPS > C 5. Chronic infection/Malignancy/HIV/Pregnancy

Design outcomes

Primary

Measure	Time frame
Peritonitis 1 year Time to first peritonitis	—

Secondary

Measure	Time frame
Cardiovascular mortality 1 year time to event analysis,All-cause mortality 1 year Time to event analysis,Hospitalization 1 year Time to event analysis,Technique failure 1 year Time to event analysis	—

Countries

Thailand

Contacts

Public ContactWatthikorn Pichitporn

Nephrology unit, Department of medicine, Faculty of medicine, Chulalongkorn university

nummon868@msn.com0816439085

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026